Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DART
NCT06940297Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2025
- Primary completion
- Aug 2031
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib and quercetin in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoint: Minimal residual disease negativity rate at 3 months. Started Sep 2025; status: recruiting.
02
Drugs
dasatinibquercetin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06940297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940297.